Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Incomplete clonal deletion as prerequisite for tissue-specific minor antigen tolerization
Nina Pilat, … , Fritz Wrba, Thomas Wekerle
Nina Pilat, … , Fritz Wrba, Thomas Wekerle
Published May 19, 2016
Citation Information: JCI Insight. 2016;1(7):e85911. https://doi.org/10.1172/jci.insight.85911.
View: Text | PDF
Research Article Immunology Transplantation

Incomplete clonal deletion as prerequisite for tissue-specific minor antigen tolerization

  • Text
  • PDF
Abstract

Central clonal deletion has been considered the critical factor responsible for the robust state of tolerance achieved by chimerism-based experimental protocols, but split-tolerance models and the clinical experience are calling this assumption into question. Although clone-size reduction through deletion has been shown to be universally required for achieving allotolerance, it remains undetermined whether it is sufficient by itself. Therapeutic Treg treatment induces chimerism and tolerance in a stringent murine BM transplantation model devoid of myelosuppressive recipient treatment. In contrast to irradiation chimeras, chronic rejection (CR) of skin and heart allografts in Treg chimeras was permanently prevented, even in the absence of complete clonal deletion of donor MHC-reactive T cells. We show that minor histocompatibility antigen mismatches account for CR in irradiation chimeras without global T cell depletion. Furthermore, we show that Treg therapy–induced tolerance prevents CR in a linked suppression–like fashion, which is maintained by active regulatory mechanisms involving recruitment of thymus-derived Tregs to the graft. These data suggest that highly efficient intrathymic and peripheral deletion of donor-reactive T cells for specificities expressed on hematopoietic cells preclude the expansion of donor-specific Tregs and, hence, do not allow for spreading of tolerance to minor specificities that are not expressed by donor BM.

Authors

Nina Pilat, Benedikt Mahr, Lukas Unger, Karin Hock, Christoph Schwarz, Andreas M. Farkas, Ulrike Baranyi, Fritz Wrba, Thomas Wekerle

×

Figure 4

Tolerance in Treg chimeras is maintained by active intragraft regulatory mechanisms.

Options: View larger image (or click on image) Download as PowerPoint
Tolerance in Treg chimeras is maintained by active intragraft regulatory...
(A) Schematic illustration of skin transfer experiment setup. (B) Fully mismatched Balb/c allografts from long-term (100 days) tolerant recipients from different treatment protocols are transferred onto RAG–/–-recipient mice. Legend depicts primary donor→recipient combination (BALB/c→BALB/c, n = 3; →Treg chimera, n = 7; →3-Gy chimera, n = 5; →9-Gy chimera, n = 5). (C) Selected RAG–/– recipients with secondary skin grafts are challenged with anti-CD25 (40 days after skin graft transfer; n = 3 each group). (D) Representative histology from transferred skin grafts (>8 weeks postsecondary transfer; H&E staining magnification ×200). (E) Classification of skin allograft pathology (>8 weeks after transfer, n = 3 per group). (F) Reactivity of sera (>8 weeks after skin grafting) with syngeneic (B6; dotted gray) and donor (BALB/c; black) thymocytes shown by flow cytometry through indirect staining with anti–mouse IgG. Representative histograms are shown for RAG skin graft recipients from the groups: 3-Gy chimeras, Treg chimeras after anti-CD25 treatment, and naive control after skin graft rejection. †, time of sacrifice (~d60).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts